Highest development stage: Approved by FDA in 2014

Development status: Approved

Gram-negative activity

Combination therapy

Mechanism of Action/Target pathogen: Approved for: complicated urinary tract infections, complicated intra-abdominal infections, acute pyelonephritis (kidney infection); other potential indications: hospital-acquired bacterial pneumonia/ ventilator-associated pneumonia